Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Vertex Pharmaceuticals, Inc’s stock clocked out at $408.85, up 1.15% from its previous closing price of $404.21. In other words, the price has increased by $1.15 from its previous closing price. On the day, 1.64 million shares were traded. VRTX stock price reached its highest trading level at $410.995 during the session, while it also had its lowest trading level at $403.59.
Ratios:
To gain a deeper understanding of VRTX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.40 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.95. For the most recent quarter (mrq), Quick Ratio is recorded 2.16 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Wells Fargo Upgraded its Equal Weight to Overweight on August 06, 2025, while the target price for the stock was maintained at $460.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 02 ’25 when Biller Jonathan bought 694 shares for $404.21 per share.
Bhatia Sangeeta N. sold 266 shares of VRTX for $102,860 on Aug 27 ’25. The Director now owns 4,565 shares after completing the transaction at $386.69 per share. On Aug 27 ’25, another insider, Bhatia Sangeeta N., who serves as the Director of the company, bought 266 shares for $386.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 104825323520 and an Enterprise Value of 99969916928. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.22, and their Forward P/E ratio for the next fiscal year is 19.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.20 while its Price-to-Book (P/B) ratio in mrq is 6.10. Its current Enterprise Value per Revenue stands at 8.755 whereas that against EBITDA is 20.821.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.35, which has changed by -0.10204035 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is 1.69%, while the 200-Day Moving Average is calculated to be -8.30%.
Shares Statistics:
It appears that VRTX traded 1.77M shares on average per day over the past three months and 2042890 shares per day over the past ten days. A total of 256.29M shares are outstanding, with a floating share count of 255.62M. Insiders hold about 0.30% of the company’s shares, while institutions hold 95.29% stake in the company. Shares short for VRTX as of 1757894400 were 4053668 with a Short Ratio of 2.30, compared to 1755216000 on 3700693. Therefore, it implies a Short% of Shares Outstanding of 4053668 and a Short% of Float of 1.78.
Earnings Estimates
. The current assessment of Vertex Pharmaceuticals, Inc (VRTX) involves the perspectives of 22.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $4.92, with high estimates of $5.29 and low estimates of $4.54.
Analysts are recommending an EPS of between $18.83 and $16.61 for the fiscal current year, implying an average EPS of $18.02. EPS for the following year is $20.19, with 23.0 analysts recommending between $23.32 and $18.31.
Revenue Estimates
In. The current quarter, 26 analysts expect revenue to total $3.05B. It ranges from a high estimate of $3.14B to a low estimate of $2.94B. As of. The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.77BFor the next quarter, 26 analysts are estimating revenue of $3.21B. There is a high estimate of $3.29B for the next quarter, whereas the lowest estimate is $3.1B.
A total of 30 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.13B, while the lowest revenue estimate was $11.89B, resulting in an average revenue estimate of $11.99B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.21B in the next fiscal year. The high estimate is $15.35B and the low estimate is $11.94B.
